Ravikumar Gayatri, Ananthamurthy Anuradha
Department of Pathology, St. John's Medical College, Koramangala, Bengaluru, Karnataka, India.
J Cancer Res Ther. 2014 Jul-Sep;10(3):671-5. doi: 10.4103/0973-1482.138135.
Cyclin D1 is a cell cycle regulatory gene emerging as a potentially significant oncogene in invasive breast cancers. In this study, we attempted to see the expression of Cyclin D1 in invasive ductal carcinomas of the breast in our population and correlate its expression with other known prognostic parameters.
A total of 39 cases were selected from our case files from January 2011. Immunohistochemistry for Cyclin D1 was performed and interpreted as positive when >10% of the tumor cells expressed the marker with a moderate to strong intensity of staining. Clinicopathological parameters such as laterality, focality, tumor size, grade, ductal carcinoma in situ (DCIS), axillary lymph node (ALN) metastasis, hormone receptor status and human epidermal growth factor receptor 2 status were analyzed and correlated with Cyclin D1 expression.
The patients' age ranged from 30 to 76 years (mean = 53.18). The tumors were unilateral and unifocal in 38 cases; one patient had bilateral synchronous tumors. The majority were grade2 (67.5%) and tumor size T2 (57.5%). Nearly 35% were associated with DCIS and 57.5% had ALN metastasis. Estrogen receptors (ER) and progesterone receptor (PgR) positivity was seen in 65% of the cases and 25% was triple negative. Cyclin D1 expression was seen in 67.5% of the cases in our study. Among the ER, PgR positive and Her-2 negative tumors, Cyclin D1 expression was seen in the majority of cases (92%) cases, whereas none of the triple negative tumors showed Cyclin D1 expression. The other prognostic parameters such as tumor size, grade and lymph node status did not show any association with Cyclin D 1 positivity.
Cyclin D1 expression was seen in 67.5% of ductal carcinoma and it showed a significant correlation with ER, PgR expression (92% in this study), which is in concordance with other similar studies in literature.
细胞周期蛋白D1是一种细胞周期调控基因，在浸润性乳腺癌中逐渐成为一种潜在的重要癌基因。在本研究中，我们试图观察细胞周期蛋白D1在我们研究人群的乳腺浸润性导管癌中的表达情况，并将其表达与其他已知的预后参数相关联。
从我们2011年1月的病例档案中选取了39例病例。进行了细胞周期蛋白D1的免疫组织化学检测，当超过10%的肿瘤细胞以中度至强染色强度表达该标志物时，判定为阳性。分析了临床病理参数，如肿瘤侧别、病灶范围、肿瘤大小、分级、导管原位癌（DCIS）、腋窝淋巴结（ALN）转移、激素受体状态和人表皮生长因子受体2状态，并将其与细胞周期蛋白D1表达相关联。
患者年龄范围为30至76岁（平均 = 53.18岁）。38例肿瘤为单侧单灶性；1例患者有双侧同步肿瘤。大多数为2级（67.5%），肿瘤大小为T2（57.5%）。近35%与DCIS相关，57.5%有ALN转移。65%的病例雌激素受体（ER）和孕激素受体（PgR）呈阳性，25%为三阴性。在我们的研究中，67.5%的病例可见细胞周期蛋白D1表达。在ER、PgR阳性且Her-2阴性的肿瘤中，大多数病例（92%）可见细胞周期蛋白D1表达，而所有三阴性肿瘤均未显示细胞周期蛋白D1表达。其他预后参数，如肿瘤大小、分级和淋巴结状态与细胞周期蛋白D1阳性无任何关联。
在67.5%的导管癌中可见细胞周期蛋白D1表达，且它与ER 和PgR表达显著相关（本研究中为92%），这与文献中的其他类似研究结果一致。
